Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026
Tobacco cessation treatment in pregnancy: insights from Florida Medicaid claims data.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olson Lindsay T, Sussman Leah, Moakley Margaret, Poehler Diana, Allaire Benjamin T, Roussos-Ross Kay, Hall Jaclyn M
Аннотация
INTRODUCTION: Tobacco use increases risk for serious pregnancy complications, increasing infant and maternal morbidity and mortality. Cessation treatments are safe during pregnancy, increase the likelihood of successfully quitting, and decrease risk of negative neonatal health outcomes. All Florida Medicaid plans cover evidence-based cessation treatments. This study analyzed Medicaid claims to better understand cessation treatment utilization for pregnant people enrolled in Florida Medicaid.
METHODS: We analyzed Florida Medicaid claims from 2018 to 2021 to assess utilization of tobacco cessation services among Medicaid beneficiaries with a delivery during the study period. We identified tobacco use status and perinatal episodes using diagnostic and procedural codes; we identified treatment utilization (counseling, pharmacotherapy) using procedural and prescription drug claims.
RESULTS: We identified 46 512 deliveries for people who use tobacco during the study period, making up 17.5% of all deliveries; among them, 6.3% received Medicaid covered tobacco cessation treatment during pregnancy and 2.4% postpartum. Among those treated, counseling was the most prevalent treatment during pregnancy (61.2%) and pharmacotherapy (nicotine replacement therapy and cessation medication) was the most prevalent treatment (75.8%) postpartum.
CONCLUSION: Best practices indicate that clinicians should ask pregnant patients about tobacco use at every visit, document their status, and offer brief counseling and cessation treatment. Despite cessation treatment coverage by Medicaid, our analysis indicates that few clinicians and beneficiaries are using Medicaid coverage for cessation treatment during the perinatal period. These findings suggest an opportunity to increase utilization of covered cessation services for individuals who use tobacco who are pregnant/postpartum, reducing risk factors for morbidity and mortality.
IMPLICATIONS: This study highlights the gap between tobacco use and the use of Medicaid coverage for tobacco cessation aids among pregnant and postpartum individuals enrolled in Medicaid. Efforts to periodically identify and address barriers to accessing covered cessation services can inform resource allocation to increase cessation support and reduce tobacco use in this population.
METHODS: We analyzed Florida Medicaid claims from 2018 to 2021 to assess utilization of tobacco cessation services among Medicaid beneficiaries with a delivery during the study period. We identified tobacco use status and perinatal episodes using diagnostic and procedural codes; we identified treatment utilization (counseling, pharmacotherapy) using procedural and prescription drug claims.
RESULTS: We identified 46 512 deliveries for people who use tobacco during the study period, making up 17.5% of all deliveries; among them, 6.3% received Medicaid covered tobacco cessation treatment during pregnancy and 2.4% postpartum. Among those treated, counseling was the most prevalent treatment during pregnancy (61.2%) and pharmacotherapy (nicotine replacement therapy and cessation medication) was the most prevalent treatment (75.8%) postpartum.
CONCLUSION: Best practices indicate that clinicians should ask pregnant patients about tobacco use at every visit, document their status, and offer brief counseling and cessation treatment. Despite cessation treatment coverage by Medicaid, our analysis indicates that few clinicians and beneficiaries are using Medicaid coverage for cessation treatment during the perinatal period. These findings suggest an opportunity to increase utilization of covered cessation services for individuals who use tobacco who are pregnant/postpartum, reducing risk factors for morbidity and mortality.
IMPLICATIONS: This study highlights the gap between tobacco use and the use of Medicaid coverage for tobacco cessation aids among pregnant and postpartum individuals enrolled in Medicaid. Efforts to periodically identify and address barriers to accessing covered cessation services can inform resource allocation to increase cessation support and reduce tobacco use in this population.